Future of oral antiplatelet therapy: Four challenged hypotheses

Thrombosis and Haemostasis

Volumn 101, Issue 6, 2009, Pages 1041-1043

  Serebruany, Victor L ^a   Makarov, Leonid M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PRASUGREL; TICLOPIDINE; ADENOSINE; FIBRINOGEN RECEPTOR; PIPERAZINE DERIVATIVE; PURINERGIC P2 RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE; THIENOPYRIDINE DERIVATIVE; THIOPHENE DERIVATIVE; TICAGRELOR;

ACUTE CORONARY SYNDROME; BLEEDING; BONE MARROW TOXICITY; CARDIOVASCULAR DISEASE; COLON TUMOR; COLONOSCOPY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; LONG TERM CARE; LOW DRUG DOSE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; SHORT SURVEY; STROKE; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CORONARY THROMBOSIS; COST BENEFIT ANALYSIS; HEMORRHAGE; MYOCARDIAL INFARCTION; RISK ASSESSMENT; SURVIVAL RATE;

ADENOSINE; CLINICAL TRIALS AS TOPIC; CORONARY THROMBOSIS; COST-BENEFIT ANALYSIS; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROGNOSIS; PURINERGIC P2 RECEPTOR ANTAGONISTS; PYRIDINES; RISK ASSESSMENT; SURVIVAL RATE; THIOPHENES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 67049125757     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-02-0078     Document Type: Short Survey

References (20)

1. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337. (Pubitemid 39458141)
2. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
3. Sacco RL, Diener HC, Yusuf S, et al.; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-1251.
4. Wiviott SD, Braunwald E, McCabe CH, et al.; the TRITON-TIMI 38 Investigators. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001-2015.
5. Serebruany VL. The "clopidogrel resistance" trap. Am J Cardiol 2007; 100: 1044-1046.
6. Lansky AJ, Tsuchiya Y, Brener M, et al. Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial. Catheter Cardiovasc Interv 2008; 72: 917-924.
7. Berger JS, Frye CB, Harshaw Q, et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol 2008; 52: 1693-1701.
8. Serebruany VL, Atar D. Assessment of bleeding events in clinical trials - proposal of a new classification Am J Cardiol 2007; 99: 288-290.
9. Cohen M, Diez JE, Levine GN, et al.; ACC; AHA. Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report - III. J Invasive Cardiol 2007; 19: 525-538.
10. Silber S, Richartz BM, Brilmayer M; The European Society of Cardiology (ESC). The European Society of Cardiology (ESC) guidelines for percutaneous coronary interventions (PCI). Herz 2006; 31: 836-846.
11. Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel- Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008; 51: 2028-2033. (Pubitemid 351689056)
12. Serebruany VL. Aggressive antiplatelet strategies: time to reconsider. Eur Heart J 2007; 28: 2183-2184. (Pubitemid 47432546)
13. Wiviott SD, Antman EM, Gibson CM, et al.; TRITON-TIMI 38 Investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006; 152: 627-635.
14. Wiviott SD, Antman EM, Winters KJ, et al.; JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel a novel thienopyridine P2Y(12) antagonist with clopidogrel in percutaneous coronary intervention. Circulation 2005; 111: 3366-3373.
15. Kaul S, Shah K, Diamond JA. Validity of the combined efficacy plus safety composite endpoint (Net Clinical Benefit) in TRITON-TIMI 38. Circulation 2008; 118: S819.
16. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11. (Pubitemid 18029027)
17. Serebruany VL. Platelet inhibition with prasugrel and increased cancer risks: Potential causes and implications. Am J Med 2009; 122: 407-408..
18. Serebruany VL, Midei MG, Meilman H, et al. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgrad Med J 2006; 82: 404-410. (Pubitemid 43945478)
19. Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin and clopidogrel in prospective data: The Interaction of Atorvastatin and Clopidogrel (INTERACTION Study). Arch Int Med 2004; 164: 2051-2057. (Pubitemid 39390564)
20. Angiolillo DJ. ADP receptor antagonism: what's in the pipeline? Am J Cardiovasc Drugs 2007; 7: 423-432.